A PHASE 3 RANDOMIZED, OPEN-LABEL MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF INEBILIZUMAB IN ADULT PARTICIPANTS WITH PRIMARY MEMBRANOUS NEPHROPATHY (PMN)

Registry ID

20250111

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

AMGEN CANADA INC

Last update

2026-06-26

Conditions

• PRIMARY MEMBRANOUS NEPHROPATHY

Related clinical trials

• AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF FELZARTAMAB IN PARTICIPANTS WITH PRIMARY MEMBRANOUS NEPHROPATHY (PMN) [PROMINENT]

View on source registry